Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Erlotinib (Primary) ; Bendamustine
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 21 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Jul 2013 Planned end date changed from 1 Jan 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.